FDA has approved Invokana, a SGLT2 inhibitor, to treat diabetes-related kidney disease
Invokana ( Canagliflozin ) has been approved by the U.S. Food and Drug Administration ( FDA ) to reduce the risk of end-stage kidney disease ( ESKD ) and cardiovascular events in patients with type 2 ...
read article